Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70010120

Enrollment

Registered

2006-03-29

Start date

2005-01-05

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System Coronary artery disease

Interventions

Spironolactone versus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient with known coronary artery disease 2. Chronic stable angina

Exclusion criteria

Exclusion criteria: 1. Left ventricular systolic dysfunction 2. Renal failure 3. Hyperkalaemia 4. Warfarin therapy

Design outcomes

Primary

Measure	Time frame
Improvement in endothelial function	—

Secondary

Measure	Time frame
1. Changes in brain natriuretic peptide (BNP) 2. Amino-terminal propeptide of type III procollagen (PIIINP) 3. Angiotensin converting enzyme (ACE) activity 4. Heart rate variability 5. QT dispersion	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026